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mutations, as a rare but high penetrance mutation, are 
considered following the two major known breast cancer 
susceptibility genes, BRCA1 and BRCA2, in HBOC 
development.[3] Human genomic PTEN gene locus 
on chromosome 10q23.3 contains 9 exons encoding a 
5.5 kb messenger RNA that has a 403 amino acid open 
reading frame.[4]
Whole gene sequencing was done for three genes in 
these families. The BRCA1 and BRCA2 in the proband of 
the families were normal, and no germline abnormality 
was found in these two genes that are mainly responsible 
for familial breast cancer. However, two new germline 
sequence variants were detected in the PTEN gene: 
One deletion (del T IVS4-29) and one single-nucleotide 
substitution (IVS2+65 G>A) [Figure 2a and b]. Both 
new changes found in the PTEN gene were analyzed 
by the two servers NetGene 2 and alternative splice site 
predictor. Del T IVS4-29 change was impositioned in 
NetGene 2 site, the 3’ splice site acceptor changed in the 
consensus sequences, but did not delete the consensus 
sequences. The IVS2+65 G>A variation did not cause a 
new change in splicing site.
Despite new achievements in this area, many 
factors leading to breast cancer predisposition are still 
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Sir,
Our study was designed to sequence the entire exonic 
regions and intronic junctions of the BRCA1, BRCA2, 
and PTEN genes with regard to identifying the 
influence of PTEN mutations in two Iranian families 
with familial breast cancer and BRCA1/2 wild-type 
genes [Figure 1].
Mutations in particular sets of genes are associated with 
an increased risk of hereditary breast and ovarian cancer 
(HBOC). These genes are categorized into three groups 
according to their impact on cancer susceptibility. The 
first group leading to elevated breast cancer risk (40% 
up to 85%)[1] with mutations of high penetrance include 
BCRA1, BCRA2, TP53, PTEN, and STK11.[2] PTEN 
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Figure 1: Pedigrees of the two families with familial breast cancer carrying new germline sequence variants in the PTEN gene: One deletion (del T IVS4-29) 
and one single-nucleotide substitution (IVS2+65 G>A)
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unknown, and thus need to be identified with further 
investigations.
All the investigations to promote strategies of early cancer 
diagnosis, which is critical for the survival of affected 
individuals, might be advantageous.
As the main mechanism for activating the PTEN protein is 
proteasomal degradation,[5] any changes in protein structure 
influence the integral role of it. The specific variations that 
we detected may make some mute changes in the protein 
interactions which may prevent it from performing its task. 
It can be cleared by the study of protein structure in future 
investigations.
To the best of our knowledge, the study we present 
here is the first analysis of the PTEN gene in BRCA1 
and BRCA2 wild-type breast and/or ovarian cancer in 
Iranian families.
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Figure 2: (a) Heterozygous IVS2+65 G>A of the PTEN gene. (b) Heterozygous 
del IVS4-29 of the PTEN gene
a
b
